Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Press release archive
Clinical
Clinical Update - 4D pharma treats first cancer patients in Part B of Phase I/II trial of MRx0518 in combination with Keytruda®
6 Jul 2020, 07:00
4D commences treatment of the first patients in Part B of its Phase I/II clinical trial of MRx0518…
Clinical
Clinical Update - Phase II COVID-19 study open for enrolment
2 Jul 2020, 07:00
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open for enrolment. Dosing of…
Clinical
4D hosts virtual R&D event providing updates on clinical programmes in oncology and COVID-19
5 Jun 2020, 07:45
4D's Chairman, CEO and CSO provide updates on the company’s clinical programmes in oncology and…
Clinical Update - Successful completion of immuno-oncology study safety phase
11 May 2020, 07:30
4D pharma plc announces successful completion of Part A of a Phase I/II clinical trial of MRx0518 in…
Clinical Update - Phase II COVID-19 study
20 Apr 2020, 07:00
4D announces expedited UK regulatory acceptance to commence Phase II study in COVID-19
Clinical Update - Interim analysis of Blautix Phase II study data
17 Apr 2020, 08:00
4D pharma plc today announces the key findings of a planned interim analysis in its BHT-II-0002…
4D pharma appoints Non-Executive Chairperson
17 Apr 2020, 08:00
4D pharma today announces that Prof. Axel Glasmacher, MD, has been appointed as Non-Executive…
Clinical Update - additional interim clinical data from MRx0518 combination study
17 Mar 2020, 08:00
4D presents an update on the previously reported interim data from its ongoing Phase I/II study of…
Clinical Update - 4D announce new study of MRx0518 in pancreatic cancer
6 Jan 2020, 08:00
4D pharma announces opening of a study investigating MRx0518 in combination with radiotherapy in…
Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA®
6 Nov 2019, 08:00
4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live…
4D pharma collaborates with MSD to develop Live Biotherapeutics for vaccines
8 Oct 2019, 07:00
4D pharma plc today announces that the Company has entered into a research collaboration and option…
Publication of data on neurodegenerative disease programmes
23 Sep 2019, 09:00
4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005…
Appointment of independent Non-Executive Director
27 Aug 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
Oncology Programmes Update
25 Jul 2019, 09:00
Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299…
4D pharma plc commences Phase I/II asthma trial
8 Jul 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…

BACK TO TOP